ERBB2 and gallbladder cancer: In one study, genomic ERBB2/ERBB3 mutations were shown to promote PD‐L1‐mediated immune escape in gallbladder cancer.[56] Recent studies have also shown that increased PD‐1 expression is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer.[57]